ScripThe recent removal of the Risk Evaluation and Mitigation Strategies (REMS) requirement for approved cellular CAR-T therapies for cancer was lauded as an expansion of the market from the two-in-10 el
Pink SheetThe US Food and Drug Administration’s June user fee goal calendar reflects the gravitational pull of major meetings. The month opens with the monster American Society of Clinical Oncology annual meeti
Pink SheetEngland’s health technology assessment (HTA) institute, NICE, has recommended in favor of making Pfizer’s Hympavzi (marstacimab) available on the National Health Service for preventing severe hemophil
ScripPfizer’s recent exit from gene therapies was not an indictment of the safety and efficacy of gene and cellular therapies. Rather it was the latest example of the difficulties in commercializing these